- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.03. | Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2 | 3 | Cision News | ||
| 13.03. | Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters | 1 | Cision News | ||
| 07.03. | The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025 | 2 | Cision News | ||
| 03.03. | ELICERA THERAPEUTICS: Elicera's CEO: "TO2 is a highly attractive opportunity to increase ownership in Elicera" | 2 | Cision News | ||
| 28.02. | Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 2 | Cision News | ||
| 28.02. | Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics | 1 | Cision News | ||
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 243 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 25.02. | Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million | 1 | Cision News | ||
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.02. | The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85 | 2 | Cision News | ||
| 12.02. | Elicera Therapeutics receives partial payment of 0,5 MEur from EIC | 3 | Cision News | ||
| 12.02. | Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme | 2 | Cision News | ||
| 10.02. | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans | 8 | Cision News | ||
| 05.02. | ELICERA THERAPEUTICS: Elicera's CEO: "2025 is a crucial year for us" | 1 | Cision News | ||
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 88 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen | |
| 28.01. | ELICERA THERAPEUTICS: Elicera's CEO: "All signs of the disease disappeared in the first patient" | 1 | Cision News | ||
| 21.01. | Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference | 2 | Cision News | ||
| 15.01. | ELICERA THERAPEUTICS: Elicera's candidate ELC-100 granted Orphan Drug Designation | 4 | Cision News | ||
| 13.01. | Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors | 2 | Cision News | ||
| 28.11.24 | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim Report 1 January - 30 September 2024 | 80 | GlobeNewswire (Europe) | Third quarter (July-September 2024)
Operating profit/loss amounted to SEK -2,697,267 (-5,149,440).
Loss for the period amounted to SEK -2,514,629 (-5,046,574).
Cash flow from operating activities... ► Artikel lesen | |
| 27.11.24 | ELICERA THERAPEUTICS: Elicera's CEO: "ELC-100 stands apart from all other standard treatments" | 1 | Cision News |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,165 | +1,73 % | Evotec, NetraMark, Novo Nordisk - vom Labor zur goldenen digitalen Zukunft mit Künstlicher Intelligenz | Die Pharmabranche erlebt eine Revolution, die alles verändert! Künstliche Intelligenz jagt durch die Labore und schneidet alte Zöpfe ab. Algorithmen durchforsten Milliarden chemischer Strukturen in... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 586,00 | -0,10 % | Japan's MHLW authorises Regeneron and Sanofi's Dupixent for COPD | ||
| BRAIN BIOTECH | 2,360 | +3,96 % | EQS-News: BRAIN Biotech AG: Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Hauptversammlung
Ergebnisse der Hauptversammlung 2025 zum Finanzjahr 2023/24 der BRAIN Biotech AG
18.03.2025 / 16:45 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,156 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,921 | +3,48 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,057 | -4,03 % | Burcon NutraScience Aktie: Beeindruckende Leistung enthüllt! | Das Unternehmen meldet Fortschritte durch strategische Expansion im Proteinmarkt und verzeichnet ein Umsatzplus von 10 Prozent bei gleichzeitiger Reduzierung der Verluste. Burcon NutraScience Corporation... ► Artikel lesen | |
| CSL | 145,76 | +2,23 % | Down 11% in 2025, are CSL shares a good buy right now? | ||
| MANNKIND | 4,525 | -2,81 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,230 | -0,81 % | Oxford Nanopore Tech - Director/PDMR Shareholding | ||
| OCULAR THERAPEUTIX | 6,858 | +1,24 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,177 | -4,84 % | Adaptimmune Therapeutics (NASDAQ:ADAP) Given New $1.75 Price Target at Guggenheim | ||
| CODEXIS | 2,524 | +1,28 % | CODEXIS, INC. - 8-K, Current Report | ||
| TELO GENOMICS | 0,030 | 0,00 % | Telo Genomics Corp.: Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors | Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests... ► Artikel lesen | |
| BIORA THERAPEUTICS | 1,260 | -100,00 % | Biora Therapeutics, Inc.: Biora Therapeutics Undertakes Chapter 11 Sale Process to Position Business for Future Growth | Sale process will help enable next stage of product development Secures up to $10.25 million in new financing to support ongoing business operations SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Biora... ► Artikel lesen | |
| CORMEDIX | 5,800 | +1,75 % | CorMedix, Inc.: CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | ? Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ? ? Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ? ? Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ? BERKELEY... ► Artikel lesen |
ELICERA THERAPEUTICS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +22,55 % bei einem Aktienkurs von 0,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.
